High throughput drug screening

被引：10

作者：

Heemskerk, J ^{[1
]}

机构：

[1] NINDS, Bethesda, MD 20892 USA

来源：

AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS | 2004年 / 5卷

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1080/17434470410019735

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：19 / 21

页数：3

共 7 条

[1] Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients [J].

Andreassi, C ;

Jarecki, J ;

Zhou, JH ;

Coovert, DD ;

Monani, UR ;

Chen, XC ;

Whitney, M ;

Pollok, B ;

Zhang, ML ;

Androphy, E ;

Burghes, AHM .

HUMAN MOLECULAR GENETICS, 2001, 10 (24) :2841-2849

[2] The challenge of translational research - a perspective from the NINDS [J].

Finkelstein, R ;

Miller, T ;

Baughman, R .

NATURE NEUROSCIENCE, 2002, 5 (Suppl 11) :1029-1030

[3]

Ghadge GD, 1997, J NEUROSCI, V17, P8756

[4] From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials [J].

Heemskerk, J ;

Tobin, AJ ;

Ravina, B .

NATURE NEUROSCIENCE, 2002, 5 (Suppl 11) :1027-1029

[5]

Heemskerk Jill, 2002, Trends in Neurosciences, V25, P494, DOI 10.1016/S0166-2236(02)02236-1

[6] Discovery of compounds that will prevent tau pathology [J].

Kosik, KS ;

Ahn, J ;

Stein, R ;

Yeh, LA .

JOURNAL OF MOLECULAR NEUROSCIENCE, 2002, 19 (03) :261-266

[7]

Smith A, 2002, NATURE, V418, P453, DOI 10.1038/418453b

← 1 →